Arcutis Biotherapeutics’ Launches ZORYVE to Treat Plague Psoriasis

Arcutis Biotherapeutics, Inc. (Arcutis)), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, recently announced that ZORYVE (roflumilast) cream 0.3% for topical use is now available in the United States for the treatment of plaque psoriasis in people aged 12 and older.

As the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of plaque psoriasis, ZORYVE clears plaques and reduces itch rapidly in all affected areas of the body, including intertriginous areas (areas of skin-to-skin contact).

Featuring HydroARQ Technology™, a patient-friendly formulation that absorbs quickly and spreads easily, ZORYVE is an effective, well-tolerated, once-daily steroid-free cream with no restrictions on duration of use.

Arcutis strategy is to unlock broad, high-quality access to ZORYVE.

  • Responsible pricing: Designed to obtain broad and rapid coverage.
  • Reduced prescriber burden: Key to maximizing volume opportunity.
  • Rapid follow-on indications: Allow for portfolio volumes across multiple indications.

ZORYVE is now available via ZORYVE Direct pharmacies and was to be available for ordering at pharmacies nationwide no later than August 15, 2022.

ZORYVE Direct pharmacies are contracted pharmacy partners that help commercially insured individuals with plaque psoriasis get access to and start ZORYVE treatment quickly and easily as prescribed by their healthcare provider.

Additionally, ZORYVE Direct pharmacies help patients navigate the payer process, lower the out-of-pocket cost for eligible patients, and offer programs that support staying on therapy.

ZORYVE Direct pharmacies are:

  • Carepoint Specialty Pharmacy: is a full-service independent specialty pharmacy servicing patients, physicians, and providers nationwide.
  • Phil: is a commercialization partner for innovative life sciences companies, offering pharmaceutical manufacturers a modern alternative to traditional access, affordability and distribution options.


Takeaway: Arcutis identified approximately 2 million psoriasis patients are treated topically by prescription by U.S. dermatologists